TrialNature cancer2026

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Peter Schmid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.